Stockreport

Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell Therapy Program for the Treatment of Refractory Angina

Caladrius Biosciences, Inc.  (CLBS) 
Last caladrius biosciences, inc. earnings: 11/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: caladrius.com/investors/overview
PDF BASKING RIDGE, N.J., March 06, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical [Read more]